Cisatracurium Besilate

ApprovedSmall molecule

Cisatracurium Besilate is one of 38 small molecule programs targeting Intracranial Hypertension. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intracranial HypertensionActive, not recruiting

Oxidative StressActive, not recruiting

Intracranial HypertensionApproved

Active, not recruiting

Oxidative StressApproved

Active, not recruiting

Competition

Competitive Landscape

138 competitors in Oxidative Stress

#DrugCompanyPhaseTrials

Kerendia

Bayer

Phase 3

1 2

Qvar

SSchering-Plough

Phase 3

1 3

Ascorbate

FFudan University

Phase 3

1 4

Cisatracurium Besilate

UUniversity Hospital, Clermont-Ferrand

Approved

1 5

Niacin/laropiprant

Merck & Co.

Phase 3

1 6

Pterostilbene

UUniversity of Mississippi Medical Center

Phase 3

1 7

Bayer Aspirin

Bayer

Preclinical

1 8

Nicorette

Pfizer

Preclinical

1 9

Tractocile

GSK

Preclinical

1 10

Circadin

NNeurim Pharmaceuticals Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oxidative Stress1 trial

Effect of Induction and Maintenance of Anesthesia With Etomidate on Hemodynamics and Oxidative Stress in Diabetic Patients

Unknown status·ZZhujiang Hospital·Phase 4·NCT02202239·60 enrolled

Neuromuscular Blocking Agents1 trial

Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients

Completed·AAssistance Publique Hopitaux De Marseille·Phase 4·NCT00299650·340 enrolled

Intracranial Hypertension1 trial

Treatment of Intracranial Hypertension of Severe Tramatic Brain Injured Patients. Physiopathologic Effects of Neuromuscular Blocking Agents

Unknown status·UUniversity Hospital, Clermont-Ferrand·Phase 4·NCT02404779·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Cisatracurium Besilate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cisatracurium Besilate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cisatracurium Besilate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Clermont-Ferrand company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity Hospital, Clermont-Ferrand

Cisatracurium Besilate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Oxidative Stress1 trial

Neuromuscular Blocking Agents1 trial

Intracranial Hypertension1 trial

References

Drug Info

Quick Facts

Related News